BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis

Samantha A. Chalmers, Elizabeth Glynn, Sayra J. Garcia, Mark Panzenbeck, Josephine Pelletier, Janice Dimock, Elise Seccareccia, Todd Bosanac, Sara Khalil, Christian Harcken, Deborah Webb, Gerald Nabozny, Jay S. Fine, Donald Souza, Elliott Klein, Leal Herlitz, Meera Ramanujam, Chaim Putterman

Research output: Contribution to journalArticle

Abstract

Lupus nephritis is a common disease manifestation of SLE, in which immune complex deposition and macrophage activation are important contributors to disease pathogenesis. Bruton's tyrosine kinase (BTK) plays an important role in both B cell and FcgammaR mediated myeloid cell activation. In the current study, we examined the efficacy of BI-BTK-1, a recently described irreversible BTK inhibitor, in the classical NZB × NZW F1 (NZB/W) and MRL/lpr spontaneous mouse models of SLE. NZB/W mice were randomly assigned to a treatment (0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg) or control group and began treatment at 22 weeks of age. The experimental setup was similar in MRL/lpr mice, but with a single treated (10 mg/kg, beginning at 8–9 weeks of age) and control group. A separate experiment was performed in the MRL/lpr strain to assess the ability of BI-BTK-1 to reverse established kidney disease. Early treatment with BI-BTK-1 significantly protected NZB/W and MRL/lpr mice from the development of proteinuria, correlating with significant renal histological protection, decreased anti-DNA titers, and increased survival in both strains. BI-BTK-1 treated mice displayed a significant decrease in nephritis-associated inflammatory mediators (e.g. LCN2 and IL-6) in the kidney, combined with a significant inhibition of immune cell infiltration and accumulation. Importantly, BI-BTK-1 treatment resulted in the reversal of established kidney disease. BTK inhibition significantly reduced total B cell numbers and all B cell subsets (immature, transitional, follicular, marginal zone, and class switched) in the spleen of NZB/W mice. Overall, the significant efficacy of BI-BTK-1 in ameliorating multiple pathological endpoints associated with kidney disease in two distinct murine models of spontaneous lupus nephritis provides a strong rationale for BTK inhibition as a promising treatment approach for lupus nephritis.

Original languageEnglish (US)
Pages (from-to)205-218
Number of pages14
JournalClinical Immunology
Volume197
DOIs
StatePublished - Dec 1 2018

Fingerprint

Lupus Nephritis
Kidney Diseases
Inbred MRL lpr Mouse
Inbred NZB Mouse
B-Lymphocytes
Agammaglobulinaemia tyrosine kinase
B-Lymphocyte Subsets
Kidney
Therapeutics
Control Groups
Macrophage Activation
Nephritis
Myeloid Cells
Antigen-Antibody Complex
Proteinuria
Interleukin-6
Spleen
Age Groups
Cell Count

Keywords

  • Bruton's tyrosine kinase
  • Lupus nephritis
  • MRL/lpr
  • NZB/W.
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Chalmers, S. A., Glynn, E., Garcia, S. J., Panzenbeck, M., Pelletier, J., Dimock, J., ... Putterman, C. (2018). BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clinical Immunology, 197, 205-218. https://doi.org/10.1016/j.clim.2018.10.008

BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. / Chalmers, Samantha A.; Glynn, Elizabeth; Garcia, Sayra J.; Panzenbeck, Mark; Pelletier, Josephine; Dimock, Janice; Seccareccia, Elise; Bosanac, Todd; Khalil, Sara; Harcken, Christian; Webb, Deborah; Nabozny, Gerald; Fine, Jay S.; Souza, Donald; Klein, Elliott; Herlitz, Leal; Ramanujam, Meera; Putterman, Chaim.

In: Clinical Immunology, Vol. 197, 01.12.2018, p. 205-218.

Research output: Contribution to journalArticle

Chalmers, SA, Glynn, E, Garcia, SJ, Panzenbeck, M, Pelletier, J, Dimock, J, Seccareccia, E, Bosanac, T, Khalil, S, Harcken, C, Webb, D, Nabozny, G, Fine, JS, Souza, D, Klein, E, Herlitz, L, Ramanujam, M & Putterman, C 2018, 'BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis', Clinical Immunology, vol. 197, pp. 205-218. https://doi.org/10.1016/j.clim.2018.10.008
Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J et al. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Clinical Immunology. 2018 Dec 1;197:205-218. https://doi.org/10.1016/j.clim.2018.10.008
Chalmers, Samantha A. ; Glynn, Elizabeth ; Garcia, Sayra J. ; Panzenbeck, Mark ; Pelletier, Josephine ; Dimock, Janice ; Seccareccia, Elise ; Bosanac, Todd ; Khalil, Sara ; Harcken, Christian ; Webb, Deborah ; Nabozny, Gerald ; Fine, Jay S. ; Souza, Donald ; Klein, Elliott ; Herlitz, Leal ; Ramanujam, Meera ; Putterman, Chaim. / BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. In: Clinical Immunology. 2018 ; Vol. 197. pp. 205-218.
@article{ec6c298089bd4b23b676a21991ebc778,
title = "BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis",
abstract = "Lupus nephritis is a common disease manifestation of SLE, in which immune complex deposition and macrophage activation are important contributors to disease pathogenesis. Bruton's tyrosine kinase (BTK) plays an important role in both B cell and FcgammaR mediated myeloid cell activation. In the current study, we examined the efficacy of BI-BTK-1, a recently described irreversible BTK inhibitor, in the classical NZB × NZW F1 (NZB/W) and MRL/lpr spontaneous mouse models of SLE. NZB/W mice were randomly assigned to a treatment (0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg) or control group and began treatment at 22 weeks of age. The experimental setup was similar in MRL/lpr mice, but with a single treated (10 mg/kg, beginning at 8–9 weeks of age) and control group. A separate experiment was performed in the MRL/lpr strain to assess the ability of BI-BTK-1 to reverse established kidney disease. Early treatment with BI-BTK-1 significantly protected NZB/W and MRL/lpr mice from the development of proteinuria, correlating with significant renal histological protection, decreased anti-DNA titers, and increased survival in both strains. BI-BTK-1 treated mice displayed a significant decrease in nephritis-associated inflammatory mediators (e.g. LCN2 and IL-6) in the kidney, combined with a significant inhibition of immune cell infiltration and accumulation. Importantly, BI-BTK-1 treatment resulted in the reversal of established kidney disease. BTK inhibition significantly reduced total B cell numbers and all B cell subsets (immature, transitional, follicular, marginal zone, and class switched) in the spleen of NZB/W mice. Overall, the significant efficacy of BI-BTK-1 in ameliorating multiple pathological endpoints associated with kidney disease in two distinct murine models of spontaneous lupus nephritis provides a strong rationale for BTK inhibition as a promising treatment approach for lupus nephritis.",
keywords = "Bruton's tyrosine kinase, Lupus nephritis, MRL/lpr, NZB/W., Systemic lupus erythematosus",
author = "Chalmers, {Samantha A.} and Elizabeth Glynn and Garcia, {Sayra J.} and Mark Panzenbeck and Josephine Pelletier and Janice Dimock and Elise Seccareccia and Todd Bosanac and Sara Khalil and Christian Harcken and Deborah Webb and Gerald Nabozny and Fine, {Jay S.} and Donald Souza and Elliott Klein and Leal Herlitz and Meera Ramanujam and Chaim Putterman",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.clim.2018.10.008",
language = "English (US)",
volume = "197",
pages = "205--218",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis

AU - Chalmers, Samantha A.

AU - Glynn, Elizabeth

AU - Garcia, Sayra J.

AU - Panzenbeck, Mark

AU - Pelletier, Josephine

AU - Dimock, Janice

AU - Seccareccia, Elise

AU - Bosanac, Todd

AU - Khalil, Sara

AU - Harcken, Christian

AU - Webb, Deborah

AU - Nabozny, Gerald

AU - Fine, Jay S.

AU - Souza, Donald

AU - Klein, Elliott

AU - Herlitz, Leal

AU - Ramanujam, Meera

AU - Putterman, Chaim

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Lupus nephritis is a common disease manifestation of SLE, in which immune complex deposition and macrophage activation are important contributors to disease pathogenesis. Bruton's tyrosine kinase (BTK) plays an important role in both B cell and FcgammaR mediated myeloid cell activation. In the current study, we examined the efficacy of BI-BTK-1, a recently described irreversible BTK inhibitor, in the classical NZB × NZW F1 (NZB/W) and MRL/lpr spontaneous mouse models of SLE. NZB/W mice were randomly assigned to a treatment (0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg) or control group and began treatment at 22 weeks of age. The experimental setup was similar in MRL/lpr mice, but with a single treated (10 mg/kg, beginning at 8–9 weeks of age) and control group. A separate experiment was performed in the MRL/lpr strain to assess the ability of BI-BTK-1 to reverse established kidney disease. Early treatment with BI-BTK-1 significantly protected NZB/W and MRL/lpr mice from the development of proteinuria, correlating with significant renal histological protection, decreased anti-DNA titers, and increased survival in both strains. BI-BTK-1 treated mice displayed a significant decrease in nephritis-associated inflammatory mediators (e.g. LCN2 and IL-6) in the kidney, combined with a significant inhibition of immune cell infiltration and accumulation. Importantly, BI-BTK-1 treatment resulted in the reversal of established kidney disease. BTK inhibition significantly reduced total B cell numbers and all B cell subsets (immature, transitional, follicular, marginal zone, and class switched) in the spleen of NZB/W mice. Overall, the significant efficacy of BI-BTK-1 in ameliorating multiple pathological endpoints associated with kidney disease in two distinct murine models of spontaneous lupus nephritis provides a strong rationale for BTK inhibition as a promising treatment approach for lupus nephritis.

AB - Lupus nephritis is a common disease manifestation of SLE, in which immune complex deposition and macrophage activation are important contributors to disease pathogenesis. Bruton's tyrosine kinase (BTK) plays an important role in both B cell and FcgammaR mediated myeloid cell activation. In the current study, we examined the efficacy of BI-BTK-1, a recently described irreversible BTK inhibitor, in the classical NZB × NZW F1 (NZB/W) and MRL/lpr spontaneous mouse models of SLE. NZB/W mice were randomly assigned to a treatment (0.3 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg) or control group and began treatment at 22 weeks of age. The experimental setup was similar in MRL/lpr mice, but with a single treated (10 mg/kg, beginning at 8–9 weeks of age) and control group. A separate experiment was performed in the MRL/lpr strain to assess the ability of BI-BTK-1 to reverse established kidney disease. Early treatment with BI-BTK-1 significantly protected NZB/W and MRL/lpr mice from the development of proteinuria, correlating with significant renal histological protection, decreased anti-DNA titers, and increased survival in both strains. BI-BTK-1 treated mice displayed a significant decrease in nephritis-associated inflammatory mediators (e.g. LCN2 and IL-6) in the kidney, combined with a significant inhibition of immune cell infiltration and accumulation. Importantly, BI-BTK-1 treatment resulted in the reversal of established kidney disease. BTK inhibition significantly reduced total B cell numbers and all B cell subsets (immature, transitional, follicular, marginal zone, and class switched) in the spleen of NZB/W mice. Overall, the significant efficacy of BI-BTK-1 in ameliorating multiple pathological endpoints associated with kidney disease in two distinct murine models of spontaneous lupus nephritis provides a strong rationale for BTK inhibition as a promising treatment approach for lupus nephritis.

KW - Bruton's tyrosine kinase

KW - Lupus nephritis

KW - MRL/lpr

KW - NZB/W.

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85055642324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055642324&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2018.10.008

DO - 10.1016/j.clim.2018.10.008

M3 - Article

C2 - 30339790

AN - SCOPUS:85055642324

VL - 197

SP - 205

EP - 218

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -